47 studies found for:    SDF-1
Show Display Options
Rank Status Study
1 Unknown  Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
Condition: SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors
Intervention: Drug: Vildagliptin
2 Unknown  The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma
Condition: Oral Cancer
3 Unknown  The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
Conditions: Laryngeal Cancer;   Hypopharyngeal Cancer;   Metastasis
4 Recruiting Linagliptin and Mesenchymal Stem Cells: A Pilot Study
Condition: Schizophrenia
Intervention: Drug: Linagliptin
5 Active, not recruiting Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: G-CSF;   Drug: Plerixafor;   Drug: Mitoxantrone;   Drug: Etoposide;   Drug: Cytarabine
6 Active, not recruiting Diabetic Macular Edema Treated With Ozurdex (DMEO)
Condition: Diabetic Macular Edema
Intervention: Drug: OZURDEX
7 Completed NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: NOX-A12
8 Completed Effect of Sitagliptin on Endothelial Progenitor Cells
Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Sitagliptin
9 Not yet recruiting SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease
Condition: Peripheral Arterial Disease
Interventions: Biological: JVS-100;   Biological: Placebo
10 Completed Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure
Condition: Heart Failure
Intervention: Biological: ACRX-100
11 Completed Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia
Condition: Critical Limb Ischemia
Interventions: Biological: JVS-100(4 mg) or placebo/8 injections;   Biological: JVS-100(8 mg) or placebo/8 injections;   Biological: JVS-100(8 mg) or placebo/16 injections;   Biological: JVS-100(16 mg) or placebo/16 injections
12 Completed NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers
Condition: Hematopoietic Stem Cell Transplantation
Interventions: Drug: NOX-A12;   Drug: Filgrastim;   Drug: NOX-A12 in combination with Filgrastim
13 Completed An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers
Condition: Stem Cell Mobilization
Intervention: Drug: AMD3100
14 Not yet recruiting Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
Conditions: Hypoxic Ischemic Encephalopathy;   Cerebral Infarction
Interventions: Drug: Autologous cord blood;   Device: Hypothermia
15 Active, not recruiting NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: NOX-A12
16 Completed NOX-A12 First-in-human (FIH) Study
Condition: Autologous Stem Cell Transplantation
Intervention: Drug: NOX-A12
17 Completed Adiponectin and Circulating Progenitor Cells (CPC) Function
Condition: Coronary Artery Disease
Intervention: Other: exercise training
18 Completed Growth Hormone's Effect on Endothelial Progenitor Cells
Condition: Cardiovascular Disease
Intervention: Drug: Growth Hormone
19 Completed AMD3100 to Mobilize Stem Cells for Donation
Conditions: Healthy;   Blood Component Removal
Intervention: Drug: AMD3100
20 Not yet recruiting Erythropoietin in Premature Infants to Prevent Encephalopathy
Condition: Premature Infant
Interventions: Drug: Epo;   Drug: Normal saline

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years